Belsomra FDA Approval History
FDA Approved: Yes (First approved August 13, 2014)
Brand name: Belsomra
Generic name: suvorexant
Dosage form: Tablets
Treatment for: Insomnia
Belsomra (suvorexant) is an orexin receptor antagonist for use in patients with difficulty falling or staying asleep (insomnia).
Development timeline for Belsomra
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.